ClinicalTrials.gg
RecruitingNCT07657104Updated Oct 22, 2026

Developing and Implementing HPV SCREENED

An interventional study of HPV Self-collection in the ED in Cervical Cancer Screening and Human Papilloma Virus, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.

Planned enrollment
24th of 39
100 · median 155
Started
2026
with 3 others
No phase
27 of 51
5 open now
Primary completion
2027-06
later than 7 of 12 live
Registered
50th of 51
by date

Among the 51 studies in Papilloma with a site in United States, this one is the 24th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 50th registered.

Papilloma

89 studies on the registry are indexed under Papilloma; 20 are open to participants now.

Browse Papilloma studies →

Open to participants now

9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 30 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Papilloma with a site in United States, or all of them as a file.
02

Study summary

This study will assess the feasibility of implementing HPV self-sampling as a primary cervical cancer screening strategy for under-screened women in the emergency department (ED). Eligible participants will receive education and an HPV self-sampling kit to complete in the ED. Individuals with HPV-positive results will be guided to follow-up care at a local clinic.

Read the detailed description

The proposed study will implement HPV self-sampling as primary cervical screening for under-screened ED patients. The long-term goal is to increase access to cervical screening for women who may not routinely use primary care and thus face increased risk of cervical cancer. This pilot feasibility trial will implement HPV self-sampling kit distribution and navigation to follow-up care in the ED. The investigators hypothesize that ED-based in-person distribution and same-day return of HPV self-sampling kits will alleviate issues of prior mailed HPV self-sampling trials by reducing participant burden. Women (30-65 years with non-critically ill presentations) who present to the ED and are overdue for cervical screening will receive 1) cervical cancer screening education and 2) a HPV self-sampling kit where they return the kit immediately after self-sampling in the ED. ScreenNJ will navigate participants with HPV-positive results to follow-up care and management according to current standard guidelines at local clinics.

03

Conditions studied

  • Cervical Cancer Screening
  • Human Papilloma Virus
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • biological women,
  • no prior hysterectomy or cervical cancer,
  • not pregnant,
  • last Pap >3 years, last co-test >5 years, or last HPV alone test >5 years,
  • speak English or Spanish,
  • has a working cellphone,
  • NJ residency
  • ED patient

Exclusion criteria

Exclusion Criteria:

  • currently pregnant (as diagnostic procedures for cervical cancer are often deferred during pregnancy);
  • previous hysterectomy;
  • previous diagnosis of cervical cancer;
  • current menses
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    HPV SCREENED

    A single-arm pilot trial of HPV self-sampling among under-screened women in the ED

    Behavioral: HPV Self-collection in the ED

Interventions

  • BehavioralHPV Self-collection in the ED

    Participants will be asked to collect a vaginal sample for HPV screening.

06

What researchers measure

Primary outcomes

  1. Completion of ED-Based HPV Self-Sampling

    Evaluate the proportion of eligible participants who complete HPV self-sampling during the emergency department visit.

    Time frame: Day 1

Secondary outcomes

  1. HPV Self Sampling Acceptability

    Acceptability of Intervention Measure (AIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more acceptable.

    Time frame: After results notification, an average of 1 week

  2. HPV Self Sampling Feasibility

    Feasibility of Intervention Measure (FIM) scale (Weiner et al., 2017). Scale values range from 1 to 5, where higher is more feasible.

    Time frame: After results notification, an average of 1 week

  3. Screening Completion

    Proportion of HPV+ women who complete follow-up screening

    Time frame: 3 months

07

Study locations

1 of 2 sites recruiting
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Sara Heinert, PhD, MPH · Contact
  • University Hospital
    Newark, New Jersey 07103, United States
    Not yet recruiting
    • Ronald Ikechi, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jun 2027, 8 months after the start.

Of 28 interventional studies with no phase under Papilloma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 8 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 18, 2026
StartActual
Oct 15, 2026was Aug 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
Show 2 sites
  • Robert Wood Johnson University Hospital · New Brunswick, United Statesno status→Recruiting
  • University Hospital · Newark, United Statesno status→Not yet recruiting
Oct 22, 2026
Start date
Aug 20, 2026→Oct 15, 2026 (actual)
Oct 22, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedHPV KnowledgeTime frame: Day 1 and after results notification- an average of 1 week
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (1 now recruiting, 1 now not yet recruiting)
    Show 2 sites
    • Robert Wood Johnson University Hospital · New Brunswick, United Statesno status→Recruiting
    • University Hospital · Newark, United Statesno status→Not yet recruiting
    Start date Aug 20, 2026→Oct 15, 2026 (now actual)
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedHPV KnowledgeTime frame: Day 1 and after results notification- an average of 1 week
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07657104
Responsible party
Sara Heinert, PhD, MPH (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Jun 18, 2026
Start date
Oct 15, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Sara Heinert, PhD, MPH
Contact
sara.heinert@rutgers.edu
(732) 235-7872
Sara Heinert, PhD, MPH
principal investigator · Department of Emergency Medicine, Rutgers Robert Wood Johnson Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion